Kelly Martin, chief executive of Elan, has rejected criticisms of the firm’s communication with investors, saying that the dramatic fall in the firm’s share price is ‘‘massively overdone’’.
Almost €3 billion was wiped off Elan’s value after negative reaction to updates on two of its drugs. Martin said that the market may have expected too much from the phase two trials for Alzheimer’s drug AAB-001....
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team